Chimerix Inc. (NASDAQ:CMRX)’s share price was down 2.9% during trading on Thursday . The company traded as low as $4.64 and last traded at $4.64, with a volume of 229,189 shares. The stock had previously closed at $4.78.

A number of equities analysts have commented on CMRX shares. FBR & Co restated a “hold” rating on shares of Chimerix in a research note on Tuesday, May 10th. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research note on Wednesday, May 11th. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $7.00 price target on shares of Chimerix in a research note on Tuesday, August 9th. Finally, Piper Jaffray Cos. set a $12.00 price target on Chimerix and gave the company a “buy” rating in a research note on Thursday, August 18th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $15.72.

The company’s market cap is $206.11 million. The company has a 50-day moving average of $4.22 and a 200 day moving average of $4.88.

Chimerix (NASDAQ:CMRX) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.12. The company had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $1.98 million. On average, analysts anticipate that Chimerix Inc. will post ($1.78) earnings per share for the current fiscal year.

In other news, CEO M Michelle Berrey purchased 13,188 shares of the firm’s stock in a transaction dated Friday, June 24th. The shares were purchased at an average price of $3.69 per share, with a total value of $48,663.72. Following the completion of the acquisition, the chief executive officer now owns 258,821 shares in the company, valued at approximately $955,049.49. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Ernest Mario purchased 50,000 shares of the firm’s stock in a transaction dated Friday, June 24th. The stock was purchased at an average cost of $3.70 per share, for a total transaction of $185,000.00. Following the acquisition, the director now owns 381,440 shares of the company’s stock, valued at approximately $1,411,328. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Chimerix stock. Jennison Associates LLC boosted its stake in Chimerix Inc. (NASDAQ:CMRX) by 67.9% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,273,779 shares of the biopharmaceutical company’s stock after buying an additional 515,029 shares during the period. Jennison Associates LLC owned approximately 2.76% of Chimerix worth $11,400,000 at the end of the most recent reporting period.

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.